January 07, 2025
AEON Biopharma, Inc. (NYSE: AEON) (the ‘Company’), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today announced the closing of its previously announced firm commitment underwritten public offering.
Gross Proceeds to the Company
The gross proceeds to the Company were approximately $20.0 million, before deducting underwriting fees and other estimated offering expenses payable by the Company. The offering closed on January 7, 2025.
Terms of the Offering
The offering consisted of 40,000,000 Common Units, each consisting of (i) one (1) share of Common Stock, (ii) one (1) Series A Registered Common Warrant to purchase one (1) share of Common Stock per unit at an exercise price of $0.25 per share, and (iii) one (1) Series B Registered Common Warrant to purchase one (1) share of Common Stock per unit at an exercise price of $0.50 per share.
Underwriters
The offering was managed by Aegis Capital Corp., a full-service investment bank that provides a wide range of financial services, including brokerage and trading, market making, investment banking, and mergers and acquisitions advisory.
Use of Proceeds
The net proceeds from the offering will be used to fund the Company’s research and development activities, as well as for working capital purposes.
About AEON Biopharma
AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurosciences market. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau.
Management Team
The Company has built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization. The management team has a proven track record of developing and commercializing successful products, and they are committed to making AEON a leader in the field of neurosciences.
Investor Contact
For more information about the Company’s offerings or its business prospects, please contact Corey Davis, Ph.D., at LifeSci Advisors at +1 212 915 2577 or cdavis@lifesciadvisors.com.
Forward-Looking Statements
The foregoing material may contain ‘forward-looking statements’ within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects.
Risk Factors
The Company’s ability to raise financing in the future
• The possibility that AEON may be adversely affected by other economic, business, regulatory, and/or competitive factors
Disclaimer
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
